KangX, WangC, ChenD, et al.: Contributions of basal glucose and postprandial glucose concentrations to hemoglobin A1c in the newly diagnosed patients with type 2 diabetes—the preliminary study. Diabetes Technol Ther, 2015; 17:445–448.
2.
MonnierL, LapinskiH, ColetteC: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care, 2003; 26:881–885.
3.
PeterR, DunseathG, LuzioSD, et al.: Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA1c in subjects with Type 2 diabetes. Diabet Med, 2009; 26:974–980.
4.
WangJS, TuST, LeeIT, et al.: Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev, 2011; 27:79–84.
5.
KikuchiK, NezuU, ShirakawaJ, et al.: Correlations of fasting and postprandial blood glucose increments to the overall diurnal hyperglycemic status in type 2 diabetic patients: variations with levels of HbA1c. Endocr J, 2010; 57:259–266.
6.
RiddleM, UmpierrezG, DiGenioA, et al.: Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care, 2011; 34:2508–2514.
7.
SchernthanerG, GuerciB, GallwitzB, et al.: Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes. Diabetes Metab, 2010; 36:389–394.
8.
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet, 1999; 354:617–621.
9.
BonoraE, MuggeoM: Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Diabetologia, 2001; 44:2107–2114.
10.
BretzelRG, NuberU, LandgrafW, et al.: Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet, 2008; 371:1073–1084.
11.
RazI, WilsonPW, StrojekK, et al.: Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care, 2009; 32:381–386.
